Novel Influenza Neuraminidase Inhibitors - Development of Orally Bioavailable Agents

新型流感神经氨酸酶抑制剂 - 口服生物可利用药物的开发

• 批准号: 256774
• 负责人: Withers Stephen G
• 金额: $ 21.64万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-02-01 至 2013-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=256774&lang=en
• 关键词: Anti-Viral; Difluorosialic Acid; Drug Development; Influenza; Mechanism-Based Inhibition; Neuraminidase Inhibitor; Oral Bioavailability

Influenza neuraminidase (also known as a sialidase) is a clinically validated enzyme target for control of influenza infections. Of the four approved drugs that inhibit this enzyme, only Tamiflu (oseltamivir) is orally available, and thus dominates the ne

流感神经氨酸酶（也称为唾液酸酶）是临床验证的用于控制流感感染的酶靶标。在四种被批准的抑制这种酶的药物中，只有达菲（奥司他韦）是口服的，因此占主导地位。